Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients

Groll AH, Silling G, Young C, Schwerdtfeger R, Ostermann H, Heinz WJ, Gerss J, Kolve H, Lanvers-Kaminsky C, Pinheiro JP, Gammelin S, et al. (2010)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 54(10): 4143-4149.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ; ;
Alle
Abstract / Bemerkung
The combination of liposomal amphotericin B (LAMB) and caspofungin (CAS) holds promise to improve the outcome of opportunistic invasive mycoses with poor prognosis. Little is known, however, about the safety and pharmacokinetics of the combination in patients at high risk for these infections. The safety and pharmacokinetics of the combination of LAMB and CAS were investigated in a risk-stratified, randomized, multicenter phase II clinical trial in 55 adult allogeneic hematopoietic stem cell recipients (aHSCT) with granulocytopenia and refractory fever. The patients received either CAS (50 mg/day; day 1, 70 mg), LAMB (3 mg/kg of body weight/day), or the combination of both (CASLAMB) until defervescence and granulocyte recovery. Safety, development of invasive fungal infections, and survival were assessed through day 14 after the end of therapy. Pharmacokinetic sampling and analysis were performed on days 1 and 4. All three regimens were well tolerated. Premature study drug discontinuations due to grade III/IV adverse events occurred in 1/18, 2/20, and 0/17 patients randomized to CAS, LAMB, and CASLAMB, respectively. Adverse events not leading to study drug discontinuation were frequent but similar across cohorts, except for a higher frequency of hypokalemia with CASLAMB (P < 0.05). Drug exposures were similar for patients receiving combination therapy and those randomized to monotherapy. There was no apparent difference in the occurrence of proven/probable invasive fungal infections and survival through day 14 after the end of therapy. CASLAMB combination therapy in immunocompromised aHSCT patients was as safe as monotherapy with CAS or LAMB and had similar plasma pharmacokinetics, lending support to further investigations of the combination in the management of patients with invasive opportunistic mycoses.
Erscheinungsjahr
Zeitschriftentitel
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Band
54
Zeitschriftennummer
10
Seite
4143-4149
ISSN
eISSN
PUB-ID

Zitieren

Groll AH, Silling G, Young C, et al. Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2010;54(10):4143-4149.
Groll, A. H., Silling, G., Young, C., Schwerdtfeger, R., Ostermann, H., Heinz, W. J., Gerss, J., et al. (2010). Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(10), 4143-4149. doi:10.1128/AAC.00425-10
Groll, A. H., Silling, G., Young, C., Schwerdtfeger, R., Ostermann, H., Heinz, W. J., Gerss, J., Kolve, H., Lanvers-Kaminsky, C., Pinheiro, J. P., et al. (2010). Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 54, 4143-4149.
Groll, A.H., et al., 2010. Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(10), p 4143-4149.
A.H. Groll, et al., “Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients”, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 54, 2010, pp. 4143-4149.
Groll, A.H., Silling, G., Young, C., Schwerdtfeger, R., Ostermann, H., Heinz, W.J., Gerss, J., Kolve, H., Lanvers-Kaminsky, C., Pinheiro, J.P., Gammelin, S., Cornely, O.A., Wuerthwein, G.: Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 54, 4143-4149 (2010).
Groll, Andreas H., Silling, Gerda, Young, Charlotte, Schwerdtfeger, Rainer, Ostermann, Helmut, Heinz, Werner J., Gerss, Joachim, Kolve, Hedwig, Lanvers-Kaminsky, Claudia, Pinheiro, Joao Paulo, Gammelin, Sibylle, Cornely, Oliver A., and Wuerthwein, Gudrun. “Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients”. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 54.10 (2010): 4143-4149.

24 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
Wang T, Zhang T, Meng T, Li Y, Chen L, Yang Q, Dong H, Lei J, Chen L, Dong Y., J Transl Med 16(1), 2018
PMID: 29880050
Invasive Aspergillosis in Children: Update on Current Guidelines.
Apsemidou A, Petridis N, Vyzantiadis TA, Tragiannidis A., Mediterr J Hematol Infect Dis 10(1), 2018
PMID: 30210741
Meta-analysis on the Influence of Antifungal Spectrum on Effectiveness of Empirical Antifungal Therapy for Febrile Neutropenia.
Irikuchi J, Imai T, Tanaka M, Tanuma M, Orii T, Kato T., Yakugaku Zasshi 137(9), 2017
PMID: 28867698
Low Caspofungin Exposure in Patients in Intensive Care Units.
van der Elst KC, Veringa A, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis-Visser P, Uges DR, Touw DJ, Kosterink JG, van der Werf TS, Alffenaar JC., Antimicrob Agents Chemother 61(2), 2017
PMID: 27855112
Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis.
Chen K, Wang Q, Pleasants RA, Ge L, Liu W, Peng K, Zhai S., BMC Infect Dis 17(1), 2017
PMID: 28219330
Echinocandins in antifungal pharmacotherapy.
Patil A, Majumdar S., J Pharm Pharmacol 69(12), 2017
PMID: 28744860
Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H, Mahmoudjafari Z, Rockey M, Henry D, Grauer D, Aljitawi O, Abhyankar S, Ganguly S, Lin T, McGuirk J., J Oncol Pharm Pract 22(2), 2016
PMID: 25471252
Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.
Stader F, Wuerthwein G, Groll AH, Vehreschild JJ, Cornely OA, Hempel G., Pharm Res 32(6), 2015
PMID: 25522788
Impact of special patient populations on the pharmacokinetics of echinocandins.
Muilwijk EW, Lempers VJ, Burger DM, Warris A, Pickkers P, Aarnoutse RE, Brüggemann RJ., Expert Rev Anti Infect Ther 13(6), 2015
PMID: 25947367
Pharmacokinetics of caspofungin in ICU patients.
Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Colbers A, Verweij PE, Burger DM, Pickkers P, Brüggemann RJ., J Antimicrob Chemother 69(12), 2014
PMID: 25139840
Newer antifungal agents.
Larru B, Zaoutis TE., Curr Opin Pediatr 25(1), 2013
PMID: 23263025
Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.
Campoli P, Perlin DS, Kristof AS, White TC, Filler SG, Sheppard DC., J Infect Dis 208(10), 2013
PMID: 23908482
The Eagle-like effect of echinocandins: what's in a name?
Vanstraelen K, Lagrou K, Maertens J, Wauters J, Willems L, Spriet I., Expert Rev Anti Infect Ther 11(11), 2013
PMID: 24134556
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
Würthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Trame MN, Schwerdtfeger R, Ostermann H, Heinz WJ, Cornely OA, Kolve H, Boos J, Silling G, Groll AH., Antimicrob Agents Chemother 56(1), 2012
PMID: 22083471
Invasive aspergillosis: resistance to antifungal drugs.
Hadrich I, Makni F, Neji S, Abbes S, Cheikhrouhou F, Trabelsi H, Sellami H, Ayadi A., Mycopathologia 174(2), 2012
PMID: 22327841
Minimization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration.
Kontny NE, Boos J, Würthwein G, Hempel G, Boddy AV, Groll AH, Krischke M., Ther Drug Monit 34(4), 2012
PMID: 22660605
Safety and interactions of new antifungals in stem cell transplant recipients.
Girmenia C, Iori AP., Expert Opin Drug Saf 11(5), 2012
PMID: 22913714
Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia.
Shigemi A, Matsumoto K, Ikawa K, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K., Int J Antimicrob Agents 38(5), 2011
PMID: 21885259
Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.
Bochennek K, Tramsen L, Schedler N, Becker M, Klingebiel T, Groll AH, Lehrnbecher T., Clin Microbiol Infect 17(12), 2011
PMID: 21895857
Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis.
Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, Laverdiere M, Filler SG, Sheppard DC., Antimicrob Agents Chemother 55(12), 2011
PMID: 21930891

51 References

Daten bereitgestellt von Europe PubMed Central.

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA., Cancer 97(4), 2003
PMID: 12569602
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases., Clin. Infect. Dis. 34(1), 2001
PMID: 11731939
Caspofungin in combination with amphotericin B against Candida glabrata.
Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Greganti G, Giannini D, Rinaldi MG, Scalise G., Antimicrob. Agents Chemother. 49(6), 2005
PMID: 15917570
Caspofungin in combination with amphotericin B against Candida parapsilosis.
Barchiesi F, Spreghini E, Tomassetti S, Giannini D, Scalise G., Antimicrob. Agents Chemother. 51(3), 2006
PMID: 17158939
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, Smith JG, Leighton CE, Bouffard A, Dropinski JF, Balkovec J., Antimicrob. Agents Chemother. 41(11), 1997
PMID: 9371328
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ., Antimicrob. Agents Chemother. 46(3), 2002
PMID: 11850268
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
Benjamin DK Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, Clark K, Dowell JA, Schranz J, Walsh TJ., Antimicrob. Agents Chemother. 50(2), 2006
PMID: 16436720
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
Caillot D, Thiebaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, Larche J, Monchecourt F, Alfandari S, Mahi L., Cancer 110(12), 2007
PMID: 17941026

AUTHOR UNKNOWN, 2009
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group., Clin. Infect. Dis. 44(10), 2007
PMID: 17443465
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D., N. Engl. J. Med. 356(4), 2007
PMID: 17251531
Recent advances in antifungal prevention and treatment.
Groll AH, Tragiannidis A., Semin. Hematol. 46(3), 2009
PMID: 19549575

AUTHOR UNKNOWN, 2001
Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey.
Groll AH, Attarbaschi A, Schuster FR, Herzog N, Grigull L, Dworzak MN, Beutel K, Laws HJ, Lehrnbecher T., J. Antimicrob. Chemother. 57(3), 2006
PMID: 16431856
Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans.
Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA., J. Antimicrob. Chemother. 51(6), 2003
PMID: 12716772
Combination echinocandin-polyene treatment of murine mucormycosis.
Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B., Antimicrob. Agents Chemother. 52(4), 2008
PMID: 18212099
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II., Cancer 98(2), 2003
PMID: 12872348
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group., Lancet 369(9572), 2007
PMID: 17482982
Rationale for combination antifungal therapy.
Lewis RE, Kontoyiannis DP., Pharmacotherapy 21(8 Pt 2), 2001
PMID: 11501988
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C; Caspofungin Combination Therapy Study Group., Cancer 107(12), 2006
PMID: 17103444
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group., Clin. Infect. Dis. 39(11), 2004
PMID: 15578352
Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J., Clin. Infect. Dis. 41(9), 2005
PMID: 16206097
Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.
Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, Ngai AL, Kartsonis N, Chodakewitz J, Sable C., Transpl Infect Dis 6(3), 2004
PMID: 15569226
Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J; Caspofungin Invasive Candidiasis Study Group., N. Engl. J. Med. 347(25), 2002
PMID: 12490683
Combination antifungal therapy: a critical review of the evidence.
Ostrosky-Zeichner L., Clin. Microbiol. Infect. 14 Suppl 4(), 2008
PMID: 18430131
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN., Clin. Infect. Dis. 45(7), 2007
PMID: 17806055
Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia.
Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG., Am. J. Med. 72(1), 1982
PMID: 7058815
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.
Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, Spellberg B., Clin. Infect. Dis. 47(3), 2008
PMID: 18558882
Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections.
Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, Lopez J, Arranz R, Cisneros JM, Martino ML, Garcia-Sanchez PJ, Morales P, Olive T, Rovira M, Solano C., Bone Marrow Transplant. 34(1), 2004
PMID: 15122312
Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.
Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ., Antimicrob. Agents Chemother. 49(8), 2005
PMID: 16048942
Recent advances in the management of mucormycosis: from bench to bedside.
Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS., Clin. Infect. Dis. 48(12), 2009
PMID: 19435437
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA., Antimicrob. Agents Chemother. 46(3), 2002
PMID: 11850256
Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation.
Trenschel R, Ditschkowski M, Elmaagacli AH, Koldehoff M, Ottinger H, Steckel N, Hlinka M, Peceny R, Rath PM, Dermoumi H, Beelen DW., Bone Marrow Transplant. 35(6), 2005
PMID: 15756283
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.
Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I., Antimicrob. Agents Chemother. 50(2), 2006
PMID: 16436724
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS., N. Engl. J. Med. 340(10), 1999
PMID: 10072411
Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.
Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W., Antimicrob. Agents Chemother. 42(9), 1998
PMID: 9736569
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE., N. Engl. J. Med. 351(14), 2004
PMID: 15459300
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA., Antimicrob. Agents Chemother. 49(11), 2005
PMID: 16251293

AUTHOR UNKNOWN, 2008

AUTHOR UNKNOWN, 2009

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 20660670
PubMed | Europe PMC

Suchen in

Google Scholar